Cardiovascular effects of fingolimod: Relevance, detection and approach.

Abstract

Fingolimod, a structural analogue of sphingosine, is the first oral treatment available for multiple sclerosis. The presence of sphingosine-1-phosphate receptors in the sinus and atrioventricular nodes, myocardial cells, endothelial cells and arterial smooth muscle cells is responsible for fingolimod's cardiovascular effects. We provide a comprehensive review of the mechanisms of these effects and characterize their clinical relevance.

• Authors: Carlos Aguiar, Sónia Batista, Ricardo Pacheco
• Journal: Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology (Rev Port Cardiol) Vol. 34 Issue 4 Pg. 279-85 (Apr 2015) ISSN: 2174-2030 [Electronic] Portugal
• PMID: 25843307 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Chemical References

• Immunosuppressive Agents
• Fingolimod Hydrochloride

Topics

• Cardiovascular System (drug effects)
• Fingolimod Hydrochloride (pharmacology)
• Humans
• Immunosuppressive Agents (pharmacology)